CLINICAL_TRIALS
ClinicalTrials.gov record update
Shared Mechanisms Contributing to Non-Alcoholic Fatty Liver Disease (NAFLD) and Psoriatic Disease (PD) Severity With Guselkumab Therapy [EMERGE]
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT07255781
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:23.259254+00:00
- Published At
- 2026-02-23T00:00:00+00:00
- Record Updated At
- 2026-02-23
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Psoriasis (PsO)", "PsA (Psoriatic Arthritis)", "NAFLD (Nonalcoholic Fatty Liver Disease)"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-23"- protocolSection.identificationModule.nctId
"NCT07255781"- protocolSection.identificationModule.officialTitle
"Shared Mechanisms Contributing to Non-Alcoholic Fatty Liver Disease (NAFLD) and Psoriatic Disease (PD) Severity With Guselkumab Therapy [EMERGE]"- protocolSection.statusModule.overallStatus
"WITHDRAWN"- protocolSection.designModule.phases
[]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.